ليتروزول تيڤع

Country: Iżrael

Lingwa: Għarbi

Sors: Ministry of Health

Ingredjent attiv:

LETROZOLE 2.5 MG

Disponibbli minn:

TEVA PHARMACEUTICAL INDUST.LTD

Kodiċi ATC:

L02BG04

Għamla farmaċewtika:

TABLETS

Rotta amministrattiva:

PER OS

Manifatturat minn:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Grupp terapewtiku:

LETROZOLE

Indikazzjonijiet terapewtiċi:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Data ta 'l-awtorizzazzjoni:

2010-01-01